Concepedia

Nagaraj Gowda

NG

Statistics

Publications

9

Citations

364

H-Index

9

Active since

2016

Affiliations

Aurigene Discovery Technologies (India)(Current)

University of California System

Merck & Co., Inc., Rahway, NJ, USA (United States)

Columbia University Irving Medical Center

Georgetown University Medical Center

Nagaraj Gowda is an author at Aurigene Discovery Technologies (India) specializing in immunology, medicine, and immunotherapy.

ORCID

Top concepts

Publications per year

2016–2021

9

Publications

9

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi et al. · Communications Biology · 2021 · 144 citations · Full text

Suppressor of Cytokine Signaling (SOCS)1 Regulates Interleukin-4 (IL-4)-activated Insulin Receptor Substrate (IRS)-2 Tyrosine Phosphorylation in Monocytes and Macrophages via the Proteasome

Sarah McCormick, Nagaraj Gowda, Jessie Fang et al. · Journal of Biological Chemistry · 2016 · 62 citations · Full text

, , +10

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Pottayil G. Sasikumar, Raghuveer Ramachandra, Srinivas Adurthi et al. · Molecular Cancer Therapeutics · 2019 · 61 citations · Full text

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity

Tim H. Holmström, Anu‐Maarit Moilanen, Tarja Ikonen et al. · Molecular Cancer Therapeutics · 2018 · 33 citations · Full text

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey R. Ager, Matthew J. Reilley, Courtney Nicholas et al. · Journal for ImmunoTherapy of Cancer · 2016 · 17 citations · Full text

1–5 of 9